Stocktoria
Rani Therapeutics Holdings, Inc. RANI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-07-30
Rani Therapeutics Holdings, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -2346.0% | -5186.2% | — | — | -1899.1% |
| Net margin | -1817.1% | -2920.0% | — | — | -306.6% |
| FCF margin | -1151.4% | -3479.0% | — | — | -1205.4% |
| Return on assets | -50.6% | -81.9% | -58.7% | -28.3% | -6.7% |
| Return on equity | -71.5% | -859.4% | -133.5% | -41.3% | -6.9% |
| Debt / equity | 0.00× | 7.16× | 1.18× | 0.41× | 0.00× |
| Current ratio | 4.21 | 1.50 | 6.36 | 20.96 | 45.30 |
| Revenue growth | 58.9% | — | — | -100.0% | 488.1% |
Source: SEC EDGAR filings · CIK 0001856725 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.